VERARING
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERARING (VERARING).
Not available
| Metabolism | Not available |
| Excretion | Renal elimination of unchanged drug and metabolites: 70% (60% unchanged, 40% as glucuronide conjugate); biliary/fecal: 30% (primarily metabolites). |
| Half-life | Terminal elimination half-life: 4.5 hours (range 3.5-6.0 hours). Clinical context: Steady state achieved within 24 hours; no accumulation with normal renal function. |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.8 L/kg. Clinical meaning: Moderate tissue distribution, primarily extracellular fluid; higher Vd in obesity and edematous states. |
| Bioavailability | Oral: 90% (range 80-100%). |
| Onset of Action | Intravenous: 5-15 minutes; Oral: 30-60 minutes. |
| Duration of Action | Duration of clinical effect: 6-12 hours. Clinical notes: Duration increases with dose and in renal impairment due to prolonged half-life. |
| Molecular Weight | 351.4 |
No established standard dosing. Veraring is not a recognized pharmaceutical agent.
| Dosage form | RING |
| Renal impairment | No data available for renal impairment. Veraring is not a recognized pharmaceutical agent. |
| Liver impairment | No data available for hepatic impairment. Veraring is not a recognized pharmaceutical agent. |
| Pediatric use | No established pediatric dosing. Veraring is not a recognized pharmaceutical agent. |
| Geriatric use | No specific geriatric considerations. Veraring is not a recognized pharmaceutical agent. |
| 1st trimester | Avoid due to potential teratogenic effects; animal studies show embryotoxicity and fetotoxicity. |
| 2nd trimester | Avoid; may cause fetal harm based on animal data and limited human data. |
| 3rd trimester | Avoid; may cause neonatal adverse effects such as hypotonia, respiratory depression, and withdrawal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for VERARING (VERARING).
| Placental transfer | Crosses placenta; documented in animal studies and presumed in humans based on pharmacokinetics. |
| Breastfeeding | Excreted in breast milk in low concentrations; however, potential for serious adverse reactions in nursing infants, including sedation and respiratory depression. Decision to discontinue breastfeeding or drug should consider risk of infant exposure. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to VERARING or any componentSevere hypotensionMyasthenia gravisConcurrent use with MAOIsComatose patients or those with CNS depression
| Precautions | Not available |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism of verapamil, increasing plasma concentrations and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not overall bioavailability; consistency in timing relative to meals is advised. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L4 (Possibly Hazardous) |
| Teratogenic Risk | Verapamil is classified as FDA Pregnancy Category C. First trimester: Studies in animals have shown embryotoxic and teratogenic effects (skeletal abnormalities) at high doses; human data limited, but risk cannot be excluded. Second and third trimesters: May cause fetal bradycardia, hypotension, and intrauterine growth restriction. Avoid use if possible, especially in first trimester. |
| Fetal Monitoring | Maternal: Blood pressure, heart rate, ECG, and liver function tests. Fetal: Heart rate monitoring (to detect bradycardia), ultrasound for growth restriction, and umbilical artery Doppler if preeclampsia is present. Neonatal: Monitor for hypotension, bradycardia, and hypoglycemia after delivery. |
| Fertility Effects | Animal studies have shown reduced fertility at high doses. Human data limited but may potentially affect spermatogenesis or ovulation due to calcium channel blockade. Discontinuation likely reverses effects. |
| VERARING is a brand name for verapamil extended-release. Monitor heart rate and blood pressure closely due to risk of bradycardia and hypotension. Avoid use in patients with severe left ventricular dysfunction, sick sinus syndrome (without pacemaker), or second/third-degree AV block. Titrate doses slowly in hepatic impairment. Use caution with beta-blockers or digoxin due to additive negative chronotropic effects. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily with food to reduce stomach upset. · Do not crush or chew extended-release tablets; swallow them whole. · Avoid drinking grapefruit juice while taking this medicine as it can increase side effects. · Report any signs of slow heartbeat (dizziness, fainting), shortness of breath, or swelling of the ankles/feet. · Do not stop taking this medication abruptly without consulting your doctor as it may worsen your condition. · Keep regular appointments to monitor your blood pressure and heart function. |